Ask AI
Test Your Skills: Biomarkers in NSCLC
Test Your Skills: The Importance of Biomarker Testing for Patients With Advanced NSCLC

Released: September 16, 2024

Activity

Progress
1 2
Course Completed

Follow-up—First-Line Treatment
RNA-based NGS testing identifies an uncommon CCDC85A::ALK fusion. You discuss the NGS results with your patient and how the presence of an ALK rearrangement makes her eligible for targeted therapy.

Now that you have all the information needed to make informed decisions about the next steps in managing the patient’s care, you decide to recommend systemic therapy.

What first-line treatment would you recommend for this patient with an identified ALK rearrangement?